Table of Contents

2019-2024 Global Varicella Vaccine Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Varicella Vaccine Consumption 2014-2024
  • 2.1.2 Varicella Vaccine Consumption CAGR by Region
• 2.2 Varicella Vaccine Segment by Type
  • 2.2.1 Injection
  • 2.2.2 Freeze-dried powder
• 2.3 Varicella Vaccine Consumption by Type
  • 2.3.1 Global Varicella Vaccine Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Varicella Vaccine Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Varicella Vaccine Sale Price by Type (2014-2019)
• 2.4 Varicella Vaccine Segment by Application
  • 2.4.1 Kids Injection
  • 2.4.2 Adults Injection
• 2.5 Varicella Vaccine Consumption by Application
  • 2.5.1 Global Varicella Vaccine Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Varicella Vaccine Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Varicella Vaccine Sale Price by Application (2014-2019)

3 Global Varicella Vaccine by Players

• 3.1 Global Varicella Vaccine Sales Market Share by Players
  • 3.1.1 Global Varicella Vaccine Sales by Players (2017-2019)
  • 3.1.2 Global Varicella Vaccine Sales Market Share by Players (2017-2019)
• 3.2 Global Varicella Vaccine Revenue Market Share by Players
  • 3.2.1 Global Varicella Vaccine Revenue by Players (2017-2019)
  • 3.2.2 Global Varicella Vaccine Revenue Market Share by Players (2017-2019)
• 3.3 Global Varicella Vaccine Sale Price by Players
• 3.4 Global Varicella Vaccine Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Varicella Vaccine Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Varicella Vaccine Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Varicella Vaccine by Regions

• 4.1 Varicella Vaccine by Regions
  • 4.1.1 Global Varicella Vaccine Consumption by Regions
  • 4.1.2 Global Varicella Vaccine Value by Regions
• 4.2 Americas Varicella Vaccine Consumption Growth
• 4.3 APAC Varicella Vaccine Consumption Growth
• 4.4 Europe Varicella Vaccine Consumption Growth
• 4.5 Middle East & Africa Varicella Vaccine Consumption Growth

5 Americas

• 5.1 Americas Varicella Vaccine Consumption by Countries
  • 5.1.1 Americas Varicella Vaccine Consumption by Countries (2014-2019)
  • 5.1.2 Americas Varicella Vaccine Value by Countries (2014-2019)
• 5.2 Americas Varicella Vaccine Consumption by Type
• 5.3 Americas Varicella Vaccine Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Varicella Vaccine Consumption by Countries
  • 6.1.1 APAC Varicella Vaccine Consumption by Countries (2014-2019)
  • 6.1.2 APAC Varicella Vaccine Value by Countries (2014-2019)
• 6.2 APAC Varicella Vaccine Consumption by Type
• 6.3 APAC Varicella Vaccine Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Varicella Vaccine by Countries
  • 7.1.1 Europe Varicella Vaccine Consumption by Countries (2014-2019)
  • 7.1.2 Europe Varicella Vaccine Value by Countries (2014-2019)
• 7.2 Europe Varicella Vaccine Consumption by Type
• 7.3 Europe Varicella Vaccine Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Varicella Vaccine by Countries
  • 8.1.1 Middle East & Africa Varicella Vaccine Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Varicella Vaccine Value by Countries (2014-2019)
• 8.2 Middle East & Africa Varicella Vaccine Consumption by Type
• 8.3 Middle East & Africa Varicella Vaccine Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Varicella Vaccine Distributors
• 10.3 Varicella Vaccine Customer

11 Global Varicella Vaccine Market Forecast

• 11.1 Global Varicella Vaccine Consumption Forecast (2019-2024)
• 11.2 Global Varicella Vaccine Forecast by Regions
  • 11.2.1 Global Varicella Vaccine Forecast by Regions (2019-2024)
  • 11.2.2 Global Varicella Vaccine Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Varicella Vaccine Forecast by Type
• 11.8 Global Varicella Vaccine Forecast by Application

12 Key Players Analysis

• 12.1 Merck
  • 12.1.1 Company Details
  • 12.1.2 Varicella Vaccine Product Offered
  • 12.1.3 Merck Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Merck News
• 12.2 GSK
  • 12.2.1 Company Details
  • 12.2.2 Varicella Vaccine Product Offered
  • 12.2.3 GSK Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 GSK News
• 12.3 Shanghai Institute
  • 12.3.1 Company Details
  • 12.3.2 Varicella Vaccine Product Offered
  • 12.3.3 Shanghai Institute Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Shanghai Institute News
• 12.4 BCHT
  • 12.4.1 Company Details
  • 12.4.2 Varicella Vaccine Product Offered
  • 12.4.3 BCHT Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 BCHT News
• 12.5 Changsheng
  • 12.5.1 Company Details
  • 12.5.2 Varicella Vaccine Product Offered
  • 12.5.3 Changsheng Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Changsheng News
• 12.6 Keygen
  • 12.6.1 Company Details
  • 12.6.2 Varicella Vaccine Product Offered
  • 12.6.3 Keygen Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Keygen News
• 12.7 Green Cross
  • 12.7.1 Company Details
  • 12.7.2 Varicella Vaccine Product Offered
  • 12.7.3 Green Cross Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Green Cross News
• 12.8 Biken
  • 12.8.1 Company Details
  • 12.8.2 Varicella Vaccine Product Offered
  • 12.8.3 Biken Varicella Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Biken News

13 Research Findings and Conclusion

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
As for the global varicella vaccine industry, the industry structure is relatively concentrated. The 72.50% of market share in production is grasped by the top 5 manufacturers. The top three manufacturers are Merck, GSK and Shanghai Institute, which are close to 52 percent totally. The United States giant Merck, which has 30.40% market share in 2015, is the leader in the varicella vaccine industry. The manufacturers following Merck are GSK and Shanghai Institute, which respectively has 10.04% and 11.60% market share globally. The Shanghai Institute is the leader of China varicella vaccine industry.
The downstream industries of varicella vaccine products are kids and adults. In the recent years, with the recovery of global economic, the development of emerging countries and the rising health concern, the consumption increase of varicella vaccine will be obvious. In the foreseeable future, the varicella vaccine products will show an optimistic upward trend.
The growth rate in developed regions such as US and Europe is not very fast because they have higher product coverage. And the number of neonatal in their countries is decreasing. So the investors should pay more attention on developing countries such as south Asia, Latin America and Middle-east.

According to this study, over the next five years the Varicella Vaccine market will register a 8.0% CAGR in terms of revenue, the global market size will reach US$ 4830 million by 2024, from US$ 3050 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Varicella Vaccine business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Varicella Vaccine market by product type, application, key manufacturers and key regions and countries.

This study considers the Varicella Vaccine value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Injection
Freeze-dried powder
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Kids Injection
Adults Injection

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Merck
GSK
Shanghai Institute
BCHT
Changsheng
Keygen
Green Cross
Biken

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Varicella Vaccine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Varicella Vaccine market by identifying its various subsegments.
Focuses on the key global Varicella Vaccine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Varicella Vaccine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Varicella Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.